Bristol Myers wins approval for KRAS drug Krazati in colorectal cancer
Bristol Myers Squibb won accelerated approval on Friday to take its KRAS inhibitor to colorectal cancer patients.
Krazati will now be available for use with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.